ABSTRACT
The blaIMP-14 carbapenem resistance gene has largely previously been observed in Pseudomonas aeruginosa and Acinetobacter spp. As part of global surveillance and sequencing of carbapenem-resistant Escherichia coli, we identified a sequence type 131 strain harboring blaIMP-14 within a class 1 integron, itself nested within an ∼54-kb multidrug resistance region on an epidemic IncA/C2 plasmid. The emergence of blaIMP-14 in this context in the ST131 lineage is of potential clinical concern.
TEXT
The emergence of carbapenemases in clinically prevalent Escherichia coli lineages such as sequence type 131 (ST131) is a major problem for the management of patients infected with these strains (1, 2). Globally, five major transmissible carbapenemase enzymes predominate, represented by the KPC, OXA-48-like, NDM, VIM, and IMP families (2, 3).
An IMP metallo-beta-lactamase enzyme (IMP-1) was first detected in Japan in Pseudomonas aeruginosa in the late 1980s (4); since then, 52 genetically diverse blaIMP gene variants 738 to 747 bp in length have been identified (5). Most blaIMP variants have been isolated from either Pseudomonas or Acinetobacter spp. and demonstrate a degree of geographic structuring (6); however, some, such as blaIMP-4 and blaIMP-8, have emerged successfully in members of the family Enterobacteriaceae and are distributed over wider geographic regions (6, 7). Associations of blaIMP with E. coli ST131 have, to date, been restricted to blaIMP-4 and blaIMP-8 in Taiwan, China, and Australia (8–11). As part of the Merck Study for Monitoring Antimicrobial Resistance Trends (SMART) (1), we identified an IMP-14-producing ST131 E. coli isolate, Ecol_732, that was isolated in Bangkok, Thailand, in 2012 and was sequenced in order to ascertain the genetic structures associated with this IMP variant in ST131.
Ecoli_732 was obtained from the urine of a hospitalized elderly male with a lower urinary tract infection. The MICs of ampicillin-sulbactam, piperacillin-tazobactam, cefoxitin, ceftriaxone, ceftazidime, cefepime, ertapenem, imipenem, amikacin, and ciprofloxacin were determined with microdilution panels prepared at International Health Management Associates, Inc. (Schaumburg, IL, USA), in accordance with 2015 CLSI guidelines. It tested nonsusceptible (i.e., either intermediate or resistant) to the above-mentioned agents. The MICs of colistin and tigecycline (determined by E tests) were 0.12 and 1 mg/liter, respectively.
DNA (chromosomal plus plasmid) was extracted from pure overnight subcultures of the isolate for both PacBio (long-read) sequencing and Illumina MiSeq (short-read) sequencing with the Qiagen Genomic-tip 100/G kit and the QIAamp DNA minikit (catalogue numbers 10243 and 51304; Qiagen, Valencia, CA), respectively. Preliminary de novo assembly of PacBio reads with HGAP3 was performed; resulting contigs were annotated with Prokka (12) and then trimmed on the basis of sequence/annotation overlaps in Geneious (version 9.04) (13). One-hundred-fifty-base paired-end MiSeq reads for each of the isolates were trimmed with Trimmomatic (version 0.35) (14) and then mapped to the corresponding PacBio assemblies with BWA mem (version 0.7.9a-r786) (15). Read pileups were inspected to confirm the structural integrity of the contigs and correct any small errors in the assembled contigs. Unmapped MiSeq reads were assembled with A5MiSeq (16) in order to identify any small plasmids (<7 kb) that may have been filtered out during the size selection process implemented as part of PacBio library preparation. Additional annotation focused on resistance genes and insertion sequences was performed with reference to the ResFinder (17), PlasmidFinder (18), and ISFinder (19) databases.
The Ecol_732 genome consists of a 5,009,900-bp chromosome and six plasmids, five of which could be fully resolved. These included pEC732-IMP14 (186,826 bp, IncA/C2), pEC732_2 (129,154 bp, IncFII/FIA/FIB/col), pEC732_3 (82,588 bp, IncB/O/K/Z), pEC732_4 (4,072 bp, untyped), and pEC732_5 (1,549 bp, untyped). A partial sixth mob plasmid fragment was also present (4,204 bp, untyped). The blaIMP-14 sequence in pEC732-IMP14 differed from the reference AY553332 by a single synonymous substitution (A249C), resulting in the same amino acid sequence. It was located within a 3,791-bp class 1 integron, In687 [intI1-blaIMP-14-aac(6′)-qacEdelta-sul1]. This integron is almost identical (single nucleotide difference, A925G) to that in Achromobacter xylosoxidans strain R4, which was cultured from a urine sample, also in Thailand (GenBank accession number KJ406505).
The backbone of pEC732-IMP14 was highly similar to that of prototype type 1 IncA/C2 plasmid pRMH760 (RefSeq database accession no. NC_023898; from a Klebsiella pneumoniae strain) and other type 1 IncA/C2 plasmids (recently reviewed in reference 20), almost all of which also include a specific region designated ARI-A that contains a variable array of resistance genes and is located 1,711 bp upstream of rhs (20). Similarly, in pEC732-IMP14, the blaIMP-14-harboring integron was part of a much larger, 54,454-bp ARI-A-like region containing antimicrobial, heavy metal, and biocide resistance genes (Fig. 1), including those encoding resistance to beta-lactams (blaOXA-10, blaIMP-14), macrolides (drug efflux), rifampin (arr-2), sulfonamides (sul1), aminoglycosides [aadA1, aadB, aph(3′)-IVa, aac(6′)] chloramphenicol (cmlA7), chromate (srpC), mercury (mer operon), and quaternary ammonium compounds (qac). Some of these were part of a second, novel, integron designated In1286 (intI1-qacH-aadB-arr-2-cmlA7-blaOXA-10-aadA1).
Plasmid pEC732-IMP14 with a detailed view of the ARI-A-like 54-kb resistance region (bottom).
An alignment of pEC732-IMP14, prototype IncA/C2 type 1 plasmid pRMH760, and the only publicly available type 1 IncA/C2 sequence from Thailand, pR148 (RefSeq database accession no. NC_019380, from Aeromonas hydrophila [21]), demonstrates the genetic similarity of these plasmids (Fig. 2). All three sequences were >99% similar in the 1- to 86,573-bp region and in the ∼27.5-kb region downstream of ARI-A (Fig. 2). Differences in pEC732-IMP14 include a region of clustered single-nucleotide variants suggestive of a recombination event (region, 3,100 to 8,000 kb) and the acquisition of two integrase subunits (regions, 86,573 to 89,203 and 90,138 to 200,167 bp; Fig. 2). Interestingly, the pR148-containing A. hydrophila strain was identified on a Thai tilapia fish farm that had successively used several antimicrobial classes (21).
Alignment of pEC732-IMP14, pR148, and pRMH760 demonstrating mean percent pairwise identity over alignment columns (green, 100%; olive, 30 to 70%; red <30%; no color, 0%). Vertical black lines in the sequence bars represent differences between the nucleotide sequences with respect to the pEC732-IMP14 reference; thin horizontal black lines represent deleted regions. The repA gene, variable ARI-A resistance region, and rhs gene are indicated, as are the region of clustered single-nucleotide variants downstream of the repA region and two additional mobile genetic elements present in pEC732-IMP14 and absent from the other two sequences.
To date, blaIMP-14 has not been described in E. coli, to our knowledge, and has largely previously been reported in P. aeruginosa and Acinetobacter baumannii strains by several hospital centers in Thailand, in some cases as part of clonal outbreaks (22–25). Although blaIMP-14 is similarly associated with class 1 integrons in these cases, as in pEC732-IMP14, the wider plasmid contexts and sequences of these integrons in P. aeruginosa and A. baumannii strains have not been investigated. It is, however, conceivable that the blaIMP-14-harboring integron observed in pEC732-IMP14 and A. xylosoxidans strain R4 has been exchanged more widely with Pseudomonas and Acinetobacter spp. in Thailand. Class 1 integrons have been linked with the recent successful spread and expansion of another metallo-beta-lactamase, blaVIM, in IncA/C2 plasmids in members of the family Enterobacteriaceae in Greece (26) and blaVIM and blaIMP in Spain (27).
The presence of the extensively drug-resistant region observed here on an epidemic IncA/C2 plasmid in an E. coli ST131 strain from Thailand is therefore of concern and may represent wider, regional, horizontal dissemination of blaIMP-14 mediated by mobile genetic elements across bacterial families. The homology of pEC732-IMP14 with an A. hydrophila plasmid found on a fish farm and the presence of blaIMP-harboring plasmids in E. coli in other environmental (28) and animal sampling frames (29) suggest that the transmission network for IMP-positive E. coli may extend beyond the health care setting. Broad surveillance and control measures that are targeted at both community and health care contexts may be required to monitor and limit blaIMP dissemination.
Nucleotide sequence accession numbers.Complete sequence data for Ecol_732 have been deposited in GenBank under BioProject number PRJNA316786. The accession numbers of the sequences are CP015138 (chromosome), CP015139 (pEC732-IMP14), CP015140 (pEC732_2), CP015141 (pEC732_3), CP015142 (pEC732_4), CP015143 (pEC732_5), and CP015144 (pEC732_6 [partial sequence only]).
ACKNOWLEDGMENTS
We are grateful for the support of the Modernizing Medical Microbiology Informatics Group. We also thank Daryl Hoban and the Merck SMART surveillance team.
N.S. is currently funded through a Public Health England/University of Oxford clinical lectureship; the sequencing work was also partly funded through a previous Wellcome Trust doctoral research fellowship (099423/Z/12/Z). Additional funding support was provided by a research grant from Calgary Laboratory Services (10006465) and by the Health Innovation Challenge Fund (a parallel funding partnership between the Wellcome Trust [WT098615/Z/12/Z] and the Department of Health [grant HICF-T5-358]). This research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Programme.
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health.
FOOTNOTES
- Received 19 April 2016.
- Returned for modification 11 May 2016.
- Accepted 25 May 2016.
- Accepted manuscript posted online 31 May 2016.
- Copyright © 2016 Stoesser et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.